Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: An open-label crossover study in healthy adult volunteers

Clinical Therapeutics

Volumn 28, Issue 5, 2006, Pages 725-733

  Miner Jr , Philip B ^a   Tutuian, Radu ^b   Castell, Donald O ^b   Liu, Sherry ^c   Sostek, Mark B ^c  

^a Oklahoma Foundation for Digestive Research   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

esomeprazole; intragastric acid control; pantoprazole; proton pump inhibitor; randomized clinical trial

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; ARTICLE; CATHETER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; LABORATORY TEST; LOWER ESOPHAGUS SPHINCTER; MALE; MEAL; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE BLIND PROCEDURE; STOMACH PH; UPPER ABDOMINAL PAIN; VITAL SIGN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ALGORITHMS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OKLAHOMA; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES; TIME FACTORS;

EID: 33745971456     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.05.001     Document Type: Article

References (14)

1. +)ATPase. Nature 290 (1981) 159-161
2. DeVault K.R., Castell D.O., and American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
3. Pisegna J.R. Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 32 (2001) 27-32
4. Miner Jr. P., Katz P.O., Chen Y., and Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 98 (2003) 2616-2620
5. Rohss K., Lind T., and Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60 (2004) 531-539
6. [EMEA Web site]. ICH Topic E6. European Agency for the Evaluation of Medicinal Products. Accessed April 21, 2006. International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed April 21, 2006
7. [WMA Web site]. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Accessed April 21, 2006 (1989), WMA, Ferney-Voltaire, France. http://www.wma.net Accessed April 21, 2006
8. Gardner J.D., Rodriguez-Stanley S., and Robinson M. Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastoenterol 96 (2001) 1363-1370
9. Helander H.E., and Keeling D.J. Cell biology of gastric acid secretion. Baillieres Clin Gastroenterol 7 (1993) 1-21
10. Armstrong D., Bair D., James C., et al. Oral esomeprazole vs. intravenous pantoprazole: A comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 18 (2003) 705-711
11. [published correction appears in Aliment Pharmacol Ther. 2005;21:101 ]. Wilder-Smith C.H., Rohss K., Bondarov P., et al. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: Results of a randomized study. Aliment Pharmacol Ther 20 (2004) 1099-1104
12. Labenz J., Armstrong D., Lauritsen K., et al., Expo Study Investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: The EXPO study. Aliment Pharmacol Ther 21 (2005) 739-746
13. Bell N.J., Burget D., Howden C.I.N., et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 Suppl 1 (1992) 59-67
14. Kushner I., Rapp W., and Burtin P. Electrophoretic and immunochemical demonstration of the existence of four human pepsinogens. J Clin Invest 43 (1964) 1983-1993